NBIX Neurocrine Biosciences, Inc.
Stock · NasdaqGS · United States · Healthcare · US64125C1099
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Neurocrine Biosciences, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
164.05 USD
+2.69%
52-week range
122.14 – 186.12
Dividend yield—
Market cap16.3B
NowoTrade score
94 Grade A
Price history
Daily prices in USD.
Updated 06 Nov 2026 20:28. Information, not advice.
Results
Next results
11 Feb 2027
in 96 days · 16:00 · estimate 2.79
Last results
3.29 vs 2.75 estimated
02 Nov 2026 · Beat +19.8%
Beat the estimate
7 of 12
4 missed · 1 in line · 3 beats in a row
Average surprise
+2.4%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Feb 2027 16:00 | 2.79 | — | — | Upcoming |
| 02 Nov 2026 16:00 | 2.75 | 3.29 | +19.8% | Beat |
| 30 Jul 2026 16:00 | 1.96 | 2.85 | +45.4% | Beat |
| 05 May 2026 16:00 | 1.70 | 1.94 | +14.4% | Beat |
| 11 Feb 2026 16:00 | 2.30 | 1.88 | -18.1% | Miss |
| 28 Oct 2025 16:00 | 2.07 | 2.17 | +4.9% | Beat |
| 30 Jul 2025 16:00 | 1.50 | 1.65 | +9.6% | Beat |
| 05 May 2025 16:00 | 1.09 | 0.70 | -36.0% | Miss |
| 06 Feb 2025 16:00 | 1.93 | 1.69 | -12.4% | Miss |
| 30 Oct 2024 07:00 | 1.82 | 1.81 | -0.4% | In line |
| 01 Aug 2024 07:00 | 1.53 | 1.63 | +6.8% | Beat |
| 01 May 2024 07:00 | 1.29 | 1.20 | -6.8% | Miss |
| 07 Feb 2024 07:00 | 1.51 | 1.54 | +1.7% | Beat |
| 31 Oct 2023 07:00 | 1.33 | 1.54 | +15.8% | Beat |
| 01 Aug 2023 07:00 | 1.12 | 1.25 | +11.7% | Beat |
| 03 May 2023 07:00 | 0.74 | -0.51 | -169.4% | Miss |
| 06 Feb 2023 07:00 | 1.44 | 1.24 | -14.1% | Miss |
| 01 Nov 2022 07:00 | 1.12 | 1.08 | -3.7% | Miss |
| 04 Aug 2022 16:00 | 0.89 | 0.84 | -5.7% | Miss |
| 04 May 2022 07:00 | 0.59 | 0.30 | -49.3% | Miss |
| 11 Feb 2022 07:00 | 0.88 | 0.04 | -95.5% | Miss |
| 01 Nov 2021 16:00 | 0.80 | 0.64 | -19.6% | Miss |
| 03 Aug 2021 16:00 | 0.76 | 0.63 | -16.8% | Miss |
| 05 May 2021 16:00 | 0.72 | 0.49 | -31.8% | Miss |
| 04 Feb 2021 16:00 | 0.90 | 0.91 | +1.1% | Beat |
| 09 Nov 2020 16:00 | 1.25 | 0.97 | -22.3% | Miss |
| 03 Aug 2020 16:00 | 1.02 | 1.42 | +39.1% | Beat |
| 06 May 2020 17:00 | 0.64 | 0.82 | +28.9% | Beat |
| 04 Feb 2020 16:00 | 0.75 | 0.35 | -53.3% | Miss |
| 04 Nov 2019 16:00 | 0.64 | 0.56 | -12.9% | Miss |
| 29 Jul 2019 16:00 | 0.25 | 0.54 | +112.6% | Beat |
| 29 Apr 2019 16:00 | -0.89 | -1.12 | -26.0% | Miss |
| 05 Feb 2019 16:00 | 0.19 | 0.19 | -0.5% | In line |
| 05 Nov 2018 16:00 | 0.49 | 0.52 | +5.4% | Beat |
| 31 Jul 2018 16:00 | -0.18 | -0.07 | +60.4% | Beat |
| 30 Apr 2018 16:00 | -0.30 | -0.47 | -56.7% | Miss |
| 13 Feb 2018 16:00 | 0.16 | 0.07 | -56.7% | Miss |
| 01 Nov 2017 16:00 | -0.53 | -0.13 | +75.3% | Beat |
| 03 Aug 2017 16:00 | -0.65 | -0.68 | -4.8% | Miss |
| 09 May 2017 16:00 | -0.72 | -0.90 | -25.3% | Miss |
| 14 Feb 2017 16:00 | -0.55 | -0.51 | +7.6% | Beat |
| 02 Nov 2016 16:00 | -0.57 | -0.43 | +24.2% | Beat |
| 03 Aug 2016 16:00 | -0.49 | -0.46 | +6.7% | Beat |
| 05 May 2016 16:00 | -0.31 | -0.22 | +28.6% | Beat |
| 11 Feb 2016 16:00 | -0.35 | -0.34 | +3.6% | Beat |
| 29 Oct 2015 16:00 | -0.32 | -0.40 | -24.4% | Miss |
| 29 Jul 2015 16:00 | -0.29 | -0.28 | +4.4% | Beat |
| 30 Apr 2015 07:00 | -0.30 | -0.01 | +96.7% | Beat |
| 09 Feb 2015 16:00 | -0.24 | -0.26 | -7.6% | Miss |
| 03 Nov 2014 16:00 | -0.20 | -0.21 | -2.8% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 2.9B | +21.4% | 478.6M | 16.7% | 4.67 | +41.9% | 748.7M |
| 2024 | 2.4B | +24.8% | 341.3M | 14.5% | 3.29 | +33.2% | 557.2M |
| 2023 | 1.9B | +26.8% | 249.7M | 13.2% | 2.47 | +58.3% | 361.6M |
| 2022 | 1.5B | — | 154.5M | 10.4% | 1.56 | — | 322.9M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 29 Feb 2024 | 135.51 | 136.10 | 130.04 | 130.40 | -3.16% | 1,717,400 | |
| 28 Feb 2024 | 136.00 | 136.03 | 133.82 | 134.66 | -1.01% | 842,200 | |
| 27 Feb 2024 | 135.12 | 136.56 | 134.52 | 136.03 | +0.33% | 818,600 | |
| 26 Feb 2024 | 134.25 | 136.20 | 133.17 | 135.58 | +1.04% | 777,300 | |
| 23 Feb 2024 | 133.87 | 134.65 | 132.73 | 134.18 | +0.61% | 542,100 | |
| 22 Feb 2024 | 130.91 | 134.00 | 130.55 | 133.37 | +2.08% | 646,700 | |
| 21 Feb 2024 | 132.84 | 133.60 | 129.93 | 130.65 | -1.51% | 812,300 | |
| 20 Feb 2024 | 133.14 | 134.20 | 131.59 | 132.65 | +0.26% | 811,600 | |
| 16 Feb 2024 | 134.15 | 134.82 | 132.23 | 132.31 | -1.26% | 725,800 | |
| 15 Feb 2024 | 131.46 | 134.16 | 131.40 | 134.00 | +1.69% | 638,000 | |
| 14 Feb 2024 | 134.33 | 135.99 | 131.56 | 131.77 | -1.55% | 780,700 | |
| 13 Feb 2024 | 129.98 | 134.93 | 129.51 | 133.84 | +2.61% | 1,768,600 | |
| 12 Feb 2024 | 132.25 | 133.17 | 130.16 | 130.43 | -1.41% | 1,012,400 | |
| 09 Feb 2024 | 134.67 | 135.42 | 131.72 | 132.30 | -1.58% | 693,300 | |
| 08 Feb 2024 | 136.78 | 136.78 | 132.50 | 134.42 | -1.37% | 1,011,000 | |
| 07 Feb 2024 | 135.00 | 143.16 | 128.00 | 136.29 | -4.67% | 1,639,000 | |
| 06 Feb 2024 | 141.96 | 143.16 | 140.87 | 142.96 | +0.92% | 1,034,100 | |
| 05 Feb 2024 | 141.18 | 141.97 | 139.72 | 141.66 | -0.06% | 672,700 | |
| 02 Feb 2024 | 142.73 | 142.91 | 141.06 | 141.74 | -0.50% | 395,800 | |
| 01 Feb 2024 | 139.77 | 142.69 | 138.43 | 142.45 | +1.92% | 858,400 | |
| 31 Jan 2024 | 141.94 | 142.22 | 139.43 | 139.77 | -1.61% | 1,148,500 | |
| 30 Jan 2024 | 142.50 | 143.00 | 141.68 | 142.06 | -0.11% | 474,600 | |
| 29 Jan 2024 | 142.30 | 143.35 | 141.89 | 142.22 | +0.05% | 597,800 | |
| 26 Jan 2024 | 141.73 | 142.75 | 140.81 | 142.15 | +0.81% | 716,600 | |
| 25 Jan 2024 | 141.02 | 141.27 | 139.17 | 141.01 | +0.64% | 585,000 |
Page 28 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules (opens in a new tab) 05 Nov 2026 13:30
- Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA Capsules (opens in a new tab) Benzinga · 05 Nov 2026 09:37
- Neurocrine Biosciences: Breaking Down A Solid Quarter (opens in a new tab) SeekingAlpha · 05 Nov 2026 04:05
- Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224 (opens in a new tab) Benzinga · 04 Nov 2026 11:20
- Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation (opens in a new tab) SeekingAlpha · 04 Nov 2026 10:05
- Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost Free (opens in a new tab) SeekingAlpha · 04 Nov 2026 08:45
- Neurocrine Biosciences, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 04 Nov 2026 01:29
- Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress (opens in a new tab) 03 Nov 2026 21:05
- Is Neurocrine Biosciences (NBIX) A Bargain On Raised INGREZZA Guidance? (opens in a new tab) Simply Wall St. · 03 Nov 2026 20:09
- Neurocrine Biosciences (NBIX) Starts Phase 2 Alzheimer’s Study And Expands Doctor Education (opens in a new tab) Simply Wall St. · 03 Nov 2026 19:13
- Neurocrine Biosciences (NBIX) Stock Looks Cheap After Its 55% Five Year Run (opens in a new tab) Simply Wall St. · 03 Nov 2026 18:06
- This Biopharma Stock Hit a 6-Year High—and It Can Keep Climbing (opens in a new tab) Barrons.com · 03 Nov 2026 18:03
- Neurocrine Biosciences Delivers Strong Q3 on Vykat Rebound, RBC Says (opens in a new tab) MT Newswires · 03 Nov 2026 16:39
- NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View (opens in a new tab) Zacks · 03 Nov 2026 15:15
- Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185 (opens in a new tab) Benzinga · 03 Nov 2026 13:39
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 159.76 USD
- Market cap
- 16.3B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 22.8 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 20.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 14.3 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 24.43× | Fair | 31.09× |
| P/E (forward) | 13.75× | Good | 14.98× |
| Price / book | 4.3× | Weak | 3.87× |
| Price / sales | 4.5× | Fair | 3.42× |
| EV / EBITDA | 15.32× | Weak | 13.09× |
| Free cash flow yield | 6.1% | Good | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 64.7% | Good | 59.2% |
| Operating margin | 32% | Good | 7.8% |
| Net margin | 19% | Good | 3.4% |
| Return on equity | 20.4% | Good | 5.7% |
| Return on assets | 12.5% | Good | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 24.3% | Good | 10.8% |
| EPS growth / year | 44.1% | Good | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.12× | Good | 0.46× |
| Net debt / EBITDA | -0.27× | Good | 1.48× |
| Current ratio | 2.04× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow NBIX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.